Data Analysis of Oseltamivir Adverse Reactions in 55 Cases

Abstract

Abstract: Objective To analyze the reported data of oseltamivir ADRs and understand the post-marketing adverse reaction features of the drug in China, so as to provide references for clinical rational use and active monitoring in medical institutions. Methods The oseltamivir-related adverse reaction reports collected from Beijing Center for ADR Monitoring during 2003~2018 were organized and analyzed. Results A total of 55 reports were included in the analysis. Since 2016, the number of reported adverse reactions has increased significantly, mainly in children ≤15 years old (41 cases, 74.55%), and the involved systems-organs were mainly manifested as gastrointestinal system damage and nervous disorders. Conclusion The post-marketing safety of oseltamivir in China should be monitored actively in order to detect the drug risk signals in time and ensure medication safety of patients.

Key words: oseltamivir, adverse drug reactions, active monitoring system

CLC Number:

R994.11

ZHOU Hong, XU Ning, ZHANG Xiao, CHEN Gang, LIU Yanjie, YU Xiaojia, GONG Lili, LIU Lihong. Data Analysis of Oseltamivir Adverse Reactions in 55 Cases[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 420-424.

References

[1] Jefferson T, Jones M, Doshi P, et al.Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments[J] . BMJ, 2014, 9(348): 2545.
[2] Malosh R E, Martin E T, Heikkinen T, et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials[J]. Clin Infect Dis, 2018,66(10):1492-
1500.
[3] Ebell M H, Call M, Shinholser J.Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinicaltrials[J]. Fam Pract, 2013,30(2):125-133.
[4] 张艳荣. 1918年大流感流行情况研究文献分析[J].中华医史杂志,2012,42(3):185-190.
[5] 秦颖,赵梦娇,谭亚运,等. 中国流感大流行的百年历史[J]. 中华流行病学杂志,2018,39(8):1028-1031.
[6] 周密,李雷雷,毛晨梅,等.今年我国流感流行的深度解析[J].中华医院感染学杂志,2018,28(4):631-635.
[7] 李晓玲,王育琴,王雅葳,等. 奥司他韦安全性再聚焦-药学视角[J].药物不良反应杂志,2012,14(1):4-7.
[8] FDA.Adverse Events Reporting System(FAERS) Public Dashboard[EB/OL].(2017-09-29)[2019-04-14]. https://
fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-
9 0135608ddc13/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis.
[9] 吴双胜,杨鹏,石伟先,等. 2007-2012年北京市流感样病例和流感病原学监测[J].国际病毒学杂志,2013,20(1):11-16.
[10] 段玮,孙瑛,杨鹏,等. 2012-2015年北京市流感监测分析[J].首都公共卫生,2016,10(2):54-57.
[11] 马贵凤,祝洁,曹慧军,等. 2013-2018年我国流感流行特征分析[J].中国病原生物学杂志,2019,14(1):73-77.
[12] Molinari,N.A.,Ortega-Sanchez,et al.The annual impact of seasonal influenza in the US:measuring disease burden and costs[J].Vaccine,2007,25(27):5086-5096.
[13] 李龙芸,蔡柏蔷,王孟昭,等.磷酸奥司他韦治疗流行性感冒的多中心临床研究[J].中华内科杂志,2001,40(12):838-842.
[14] Nicholson K G,Aoki F Y,Osterhaus A D,et al.Efficacy and safety of oseltamivir in treatment of acute influenza:a randomised controlledtrial[J].Neuraminidase Inhibitor Flu Treatment Investigator Group.Lancet,2000,355:1845-
1850.
[15] 奥司他韦引起行为改变的不良反应[J]. 药物流行病学杂志,2018,17(5):280.
[16] 马小军. 奥司他韦安全性再聚焦-临床视角[J].药物不良反应杂志,2012,14(1):8-9.
[17] Stephen Toovey, Eric P. Prinssen, Craig R.Rayner. Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review[J]. Adv Ther,2012,29(10):826-848.
[18] OSE A, ITO M, KUSUHARA H, et al.Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate(Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/ Abcc4)[J]. Drug Metab Dispos, 2009,37(2):315-321.
[19] SHI D, YANG J, YANG D, et al.Anti-in?uenza prodrug oseltamivir is activated by carboxylesterase human carboxy-
lesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel[J]. J Pharmacol Exp Ther,2006,319(3):1477-1484.
[20] TOOVEY S, RAYNER C, PRINSSEN E, et al.Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review[J]. Drug Saf,2008,31(12):1097-1114.
[21] 侯永芳,沈璐,刘巍,等.美国医疗产品安全主动监测系统概述及启示[J].中国药物警戒,2017,14(1):32-35.
[22] 侯永芳,宋海波,刘红亮,等. 基于中国医院药物警戒系统开展主动监测的实践与探讨[J]. 中国药物警戒,2019,16(4):212-224.